Alzamend Neuro (ALZN) investor relations material

Company overview

• Focuses on developing treatments for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD using two proprietary therapeutics licensed from a leading research institution.

• Lead candidate AL001 is a patented ionic cocrystal of lithium, aiming to replace current lithium therapies and treat multiple neuropsychiatric disorders.

• ALZN002 is a cell-based therapeutic vaccine designed to restore immune response against Alzheimer's disease.

• Headquarters in Atlanta, Georgia, and listed on NASDAQ since June 2021.

Pipeline and clinical progress

• AL001 completed Phase I and IIA trials, showing safety, bioequivalence, and superior brain delivery compared to marketed lithium carbonate.

• Phase II trials for AL001 in bipolar disorder began in March 2026, with additional Phase II studies in Alzheimer's, MDD, and PTSD planned for 2026.

• ALZN002 Phase I/IIA trial for Alzheimer's was initiated in March 2023, paused in February 2024, and is expected to resume in 2026.

Clinical and non-clinical results

• AL001 demonstrated improved brain bioavailability, reduced systemic exposure, and a safer profile than lithium carbonate in preclinical and clinical studies.

• Preclinical studies showed AL001 reduced Alzheimer's biomarkers, improved cognition, and had fewer side effects compared to lithium carbonate.

• ALZN002 induced strong, long-lasting antibody responses in animal models without increasing inflammation, supporting its adjuvant-free vaccine approach.